Список литературы

1. Zhang S, Kipps TJ. The pathogenesis of chronic lymphocytic leukemia. Annu Rev Pathol. 2014; 9: 103 - 118.

2. Morton LM, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992 - 2001. Blood. 2006; 107(1): 265 - 76.

3. Watson L, Wyld P, Catovsky D. Disease burden of chronic lymphocytic leukaemia within the European Union. European journal of haematology. 2008; 81(4): 253 - 8.

4. Jemal A, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57(1): 43 - 66.

5. Dores GM, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol. 2007; 139(5): 809 - 19.

6. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России. 2018 г.

7. Hallek М, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018; 131(25): 2745 - 60.

8. International CLL-IPI working group. An international prognostic index for patietns with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016; 17(6): 779 - 790.

9. Morice WG, Kurtin P, Hodnefield J, et al. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients. Mayo Clinic Proceedings 2008; 83(7): 776 - 785.

10. Rawstron AC, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008; 359(6): 575 - 83.

11. Rossi D, et al. Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naive patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2009; 50(4): 604 - 11.

12. Conte MJ, et al. Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma. 2014; 55(9): 2079 - 2084.

13. CLL Trialists' Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. Journal of the National Cancer Institute 1999; 91(10): 861 - 868.

14. Hallek M, et al., Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376(9747): 1164 - 74.

15. Fischer K, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016; 127(2): 208 - 15.

16. Fischer K, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012; 30(26): 3209 - 16.

17. Eichhorst B, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016; 17(7): 928 - 42.

18. Goede V, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014; 370(12): 1101 - 10.

19. Leblond V, Laribi K, Ilhan O, et al. Rituximab in Combination with Bendamustine or Chlorambucil for Treating Patients with Chronic Lymphocytic Leukemia: Interim Results of a Phase Illb Study (MaBLe). Blood. 2012; 120: Abstract 2744.

20. Burger JA, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 373(25): 2425 - 37.

21. Burger JA, et al. Ibrutinib for First-Line Treatment of Older Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A4-Year Experience From the REASONATE-2 Study. EHA 2018, Abstract PF343.

22. Nikitin E, et al. Randomised Comparison Of FCR-Lite And ClbR (Chlorambucil Plus Rituximab) Regimens In Elderly Patients With Chronic Lymphocytic Leukemia. Hematologica. 2013; 98(s1) Abstract NS 1147.

23. Foa R, et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol. 2014; 89(5): 480 - 6.

24. Hillmen P, et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. J Clin Oncol. 2014; 32(12): 1236 - 41.

25. Catovsky D, Else M, Richards S. Chlorambucil-still not bad: a reappraisal. Clin Lymphoma Myeloma Leuk. 2011; 11 (Suppl 1): S2 - 6.

26. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003; 21: 1746 - 1751.

27. Burger JA, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a singlearm, phase 2 study. Lancet Oncol. 2014; 15(10): 1090 - 9.

28. Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after non-myeloablative conditioning. J Clin Oncol. 2008; 26(30): 4912 - 4920.

29. Dreger P, Dohner H, Ritgen M, et al; German CLL Study Group. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010; 116(14): 2438 - 2447.

30. Stilgenbauer S, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016; 17(6): 768 - 778.

31. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 2.2019. www.nccn.org

32. Tam CS, et al. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014; 124(20): 3059 - 64.

33. Fischer K, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011; 29(26): 3559 - 66.

34. Byrd, JC, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371(3): 213 - 23.

35. Moreno C, et al. Ibrutinib in previously treated chronic lymphocytic leukemia: updated efficacy and safety of the RESONATE study with up to four years of follow-up. EHA 2017, Abstract S769.

36. Chanan-Khan A, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016; 17(2): 200 - 11.

37. Fraser G, et al. Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study. iwCLL 2017, Abstract 197.

38. Seymour JF, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. New Eng J Med. 2018; 378: 1107 - 1120.

39. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil. 2011; 90 (5 Supp 1): S88 - 94.

40. Е.А. Никитин, Е.А. Стадник, С.А. Луговская и соавт. Хронический лимфолейкоз//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. - М., 2018 - с. 179 - 200.

41. Whittle AM, Allsup DJ, Bailey JR. Chronic lymphocytic leukemia is a risk factor for venous thromboembolism. Leukemia Research. 2011; 35: 419 - 421.

42. Lipsky AH, Farooqui MZH, Tian X. et al. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2015; 100(12): 1571 - 1578.

43. Parikh SA, Kay NE, Shanafelt TD. How we treat Richter syndrome. Blood. 2014; 123(11): 1647 - 57.

44. Shanafelt TD, Wang V, Kay NE, et al. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): a trial of the ECOG-ACRIN Cancer Research Group (E1912). Abstract # LBA-4. Представлено на конференции ASH Annual Meeting 2018 г.

45. Burger JA, Sivina M, Jain N, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019; 133(10): 1011 - 1019.

46. Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018; 379(26): 2517 - 2528.

47. Michallet AS, Campidelli A, Lequeu H, et al. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group. Am J Hematol. 2017; 92(6): E105 - E107.

48. Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: Systematic review and meta-analysis. Leukemia & Lymphoma 2009; 50: 764 - 772.

49. Т.С. Константинова, Г.А. Клясова, К.Д. Капланов и соавт. Лечение и профилактика инфекционных осложнений у пациентов с лимфопролиферативными заболеваниями.//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. - М., 2018, - с. 289 - 311.

50. Rubin LG, Levin MJ, Ljungman P, et al. IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2013; 58(3): 309 - 18.

51. Sinisalo M, Aittoniemi J, Oivanen P, et al. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol 2001; 114(1): 107 - 10.

52. Shanafelt TD, Drake MT, Maurer MJ, et al. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood. 2011; 117(5): 1492 - 8.